Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Sep;77(9):999-1009.
doi: 10.1111/anae.15802.

A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery

T G Coulson  1 , L F Miles  2 , A Serpa Neto  3 , D Pilcher  4 , L Weinberg  2 , G Landoni  5 , A Zarbock  6 , R Bellomo  7
Affiliations
Randomized Controlled Trial

A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery

T G Coulson et al. Anaesthesia. 2022 Sep.

Abstract

Acute kidney injury is common after cardiac surgery. Vasoplegic hypotension may contribute to kidney injury, and different vasopressors may have variable effects on kidney function. We conducted a double-blind, randomised feasibility trial comparing peri-operative angiotensin-2 with noradrenaline. We randomly allocated 60 patients at two centres to a blinded equipotent angiotensin-2 or noradrenaline infusion intra-operatively and for up to 48 h postoperatively, titrated to mean arterial pressure of 70-80 mmHg. Primary feasibility outcomes included consent rate, protocol adherence, infusion duration, mean arterial pressure maintenance in the target range and major adverse outcomes. Secondary outcomes included kidney injury rate. The consent rate was 47%. Protocol adherence was 100% in the angiotensin-2 group and 94% in the noradrenaline group. Study drug duration was median (IQR [range]) 217 (160-270 [30-315]) vs. 185 (135-301 [0-480]) min (p = 0.78) min intra-operatively, and 5 (0-16 [0-48]) vs. 14.5 (4.8-29 [0-48]) hours (p = 0.075) postoperatively for angiotensin-2 and noradrenaline, respectively. The mean arterial pressure target was achieved postoperatively in 25 of 28 (89%) of the angiotensin-2 group and 27 of 32 (84%) of the noradrenaline group. One participant had a stroke, one required extracorporeal support and three required renal replacement therapy, all in the noradrenaline group (p = 0.99, p = 0.99 and p = 0.1). Acute kidney injury occurred in 7 of 28 in the angiotensin-2 group vs. 12 of 32 patients in the noradrenaline group (p = 0.31). This pilot study suggests that a trial comparing angiotensin-2 with noradrenaline is feasible. Its findings justify further investigations of angiotensin-2 in cardiac surgery.

Keywords: angiotensin-2; cardiac surgery; kidney injury; noradrenaline; norepinephrine; randomised controlled trial; renal dysfunction; renal failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart describing management protocol for mean arterial pressure (MAP) and drug infusion during the peri‐operative period.
Figure 2
Figure 2
CONSORT diagram. *Inclusion criteria of AKI score >> 3.5; **inclusion criteria of AKI score >> 1.5; ICU, intensive care unit; OT, operating theatre.
See this image and copyright information in PMC

Comment in

References

    1. Wang Y, Bellomo R. Cardiac surgery‐associated acute kidney injury: risk factors, pathophysiology and treatment. Nature Reviews Nephrology 2017; 13: 697–711. - PubMed
    1. Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is associated with increased long‐term mortality after cardiothoracic surgery. Circulation 2009; 119: 2444–53. - PubMed
    1. Bellomo R, Giantomasso DD. Noradrenaline and the kidney: friends or foes? Critical Care 2001; 5: 294–8. - PMC - PubMed
    1. Williams JB, Hernandez AF, Li S, et al. Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS‐care study. Journal of Cardiac Surgery 2011; 26: 572–8. - PMC - PubMed
    1. Guarracino F, Habicher M, Treskatsch S, et al. Vasopressor therapy in cardiac surgery—an experts' consensus statement. Journal of Cardiothoracic and Vascular Anesthesia 2021; 35: 1018–29. - PubMed

Publication types